{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:31:50Z","timestamp":1787239910935,"version":"build-2736575974"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.1001\/jamaoncol.2026.1882","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:30:23Z","timestamp":1782401423000},"page":"807","source":"Crossref","is-referenced-by-count":0,"title":["Less Can Be More by Circulating Tumor DNA Use in\n                    <i>ERBB2<\/i>\n                    -Positive Breast Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Naoto T.","family":"Ueno","sequence":"first","affiliation":[{"name":"Translational and Clinical Research Program, University of Hawai\u02bbi Cancer Center, Honolulu"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"31","key":"ced260003r1","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1200\/JCO.23.02505","article-title":"Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update.","volume":"42","author":"Loibl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"22","key":"ced260003r2","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1200\/JCO.19.00066","article-title":"Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer.","volume":"37","author":"Tolaney","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"ced260003r3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"ced260003r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.2023","article-title":"Neoadjuvant paclitaxel, trastuzumab, and pertuzumab for stage II to III, ERBB2-positive breast cancer: a secondary analysis of the DAPHNe trial.","author":"Tarantino","journal-title":"JAMA Oncol"},{"issue":"1","key":"ced260003r5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41523-022-00429-7","article-title":"A prospective trial of treatment de-escalation following neoadjuvant paclitaxel\/trastuzumab\/pertuzumab in HER2-positive breast cancer.","volume":"8","author":"Waks","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"ced260003r6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"ced260003r7","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.3390\/cancers14205051","article-title":"Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy: a pooled analysis.","volume":"14","author":"Swain","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"16","key":"ced260003r8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1200\/JCO.2025.43.16_suppl.501","article-title":"Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2-positive breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181\/CompassHER2 pCR trial.","volume":"43","author":"Tung","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"ced260003r9","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer.","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"ced260003r10","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-18-2521","article-title":"Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO phase III trial.","volume":"25","author":"Roth\u00e9","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ced260003r11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.18632\/oncotarget.28565","article-title":"Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay.","volume":"15","author":"Northcott","year":"2024","journal-title":"Oncotarget"},{"issue":"22","key":"ced260003r12","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-23-0757","article-title":"Molecular residual disease in breast cancer: detection and therapeutic interception.","volume":"29","author":"Medford","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7","key":"ced260003r13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial.","volume":"7","author":"van der Voort","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10437","key":"ced260003r14","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-Year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2850881\/jamaoncology_ueno_2026_ed_260003_1787161702.77359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:02:48Z","timestamp":1787238168000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2850881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.1882","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}